MedTrace Logo

DIA_CENTRAL:T2D Treatment Pattern in Central Europe

NCT03807440 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4083

Last updated 2023-12-01

Study results available
· View outcomes & findings →

Summary

This is a non-interventional study using existing data including medical chart review.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Empagliflozin

Empagliflozin

DRUG

Sodium Glucose Transporter 2 inhibitor

Sodium Glucose Transporter 2 inhibitor

DRUG

Dipeptidyl-peptidase 4 inhibitor

Dipeptidyl-peptidase 4 inhibitor

DRUG

Glucagon-like peptide 1 agonist

Glucagon-like peptide 1 agonist

Sponsors & Collaborators

Principal Investigators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-26
Primary Completion
2021-08-31
Completion
2021-08-31
FDA Drug
Yes

Countries

  • Bulgaria
  • Czechia
  • Hungary
  • Poland
  • Russia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03807440 on ClinicalTrials.gov